L. Mehta

Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2.

R. Cady, M. Janelidze, D. Buse, 2022, Clinical therapeutics.

Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study

R. Lipton, R. Cady, P. Winner, 2022, The Journal of Headache and Pain.